RET and cancer: Multi-kinase inhibitors, such as Cabozantinib, Vandetanib, and Lenvatinib, have demonstrated efficacy in the treatment of RET fusion-positive cancers, but their lack of specificity and susceptibility to drug resistance have been noted.